Global Study of MK-2060 (Anti-Factor XI Monoclonal Antibody) in Participants With End Stage Renal Disease Receiving Hemodialysis (FXI Hemodialysis Study) (MK-2060-007)
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 506 participants.
Also called NCT05027074
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase
- Phase 2
- Enrolled
- 506 participants
- Sponsor
- Registry
-
NCT05027074 -
2024-511055-17-00 -
U1111-1303-0286 -
2020-002397-27
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Australia, Brazil, Bulgaria, Canada, Czechia, Germany, Greece, Italy, Portugal, Puerto Rico, Romania, Russia, Sweden
- Registry status
- Completed
Technical summary
Registry record NCT05027074. Randomized; quadruple masking; primary purpose prevention. Start 2021-09-17 (actual); primary completion 2024-10-30 (actual). Results posted on 2025-11-17.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Global Study of MK-2060 (Anti-Factor XI Monoclonal Antibody) in Participants With End Stage Renal Disease Receiving Hemodialysis (FXI Hemodialysis Study) (MK-2060-007)
- Condition
- End-Stage Renal Disease
- Condition
- End-Stage Kidney Disease
- Condition
- Kidney Failure, Chronic
- Intervention (Drug)
- MK-2060
- Intervention (Drug)
- Placebo
- Lead sponsor
- Merck Sharp & Dohme LLC
Record details
- Record id
cardio:ct-nct05027074- Content hash
14c6cb032b53b3310165d419f2bf4783b826dd894fd83392a0fd24a58b375431